Breast Cancer Clinical Trial

Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer

Summary

This is an open-label, three-part, multiple-dose study to evaluate safety, tolerability, and efficacy of U3-1402 in patients with HER3-positive metastatic breast cancer. HER3 is a unique member of the human epidermal growth factor receptor, which defines a certain type of cancer.

The number of patients and treatment cycles are not fixed in this study. Subjects who continue to derive clinical benefit from the study treatment in the absence of withdrawal of consent, progressive disease (PD), unacceptable toxicity, or death may continue the study treatment until the end of the trial.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Is 18 Years and older in the United States or 20 Years and older in Japan
Has a pathologically documented advanced/unresectable or metastatic breast cancer
Documented HER3-positive disease measured by immunohistochemistry (IHC)
Has disease that is refractory to or intolerable with standard treatment, or for which standard treatment no longer is available
Has an Eastern Cooperative Oncology Group Performance Status 0-1
Has Left Ventricular Ejection Fraction ≥ 50%

Has measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

Additional Inclusion Criteria for Dose Finding Part and Dose Expansion Part:

Has received 2-6 prior chemotherapy regimens for breast cancer, at least 2 of which were administered for treatment of advanced/unresectable or metastatic disease. At least 1 prior chemotherapeutic regimen must have included a taxane, administered in the neoadjuvant, adjuvant, or advanced setting. (With exception of Dose Expansion Part TNBC cohort. See additional inclusion criteria for Dose Expansion Part TNBC cohort.)

Additional Inclusion Criteria for Dose Expansion Part Only:

Is able to submit a fresh tumor biopsy sample prior to starting study treatment if not already submitted for HER3 expression

Has documented hormone (estrogen and/or progesterone) receptor (HR)-positive and HER2 negative expression according to American Society of Clinical Oncology - College of American Pathologists (ASCO-CAP) guidelines. (With exception of Dose Expansion Part TNBC cohort. See additional inclusion criteria for Dose Expansion Part TNBC cohort.)

Additional Inclusion Criteria for Dose Expansion Part TNBC cohort Only:

Has documented hormone (estrogen and progesterone) receptor (HR)-negative and HER2 negative expression according to American Society of Clinical Oncology - College of American Pathologists (ASCO-CAP) guidelines
Has progressed after receiving 1 to 2 prior chemotherapy regimens for advanced/unresectable or metastatic breast cancer.

Exclusion Criteria:

Prior treatment with a HER3 antibody
Prior treatment with an antibody-drug conjugate (ADC) which consists of an exatecan derivative that is a topoisomerase I inhibitor (eg, DS-8201)
Has a medical history of symptomatic congestive heart failure (New York Heart Association classes II-IV) or serious cardiac arrhythmia requiring treatment
Has a medical history of myocardial infarction or unstable angina
Has a corrected QT prolongation to > 450 millisecond (ms) in males and > 470 ms in females
Has a medical history of clinically significant lung diseases (eg, interstitial pneumonia, pneumonitis, pulmonary fibrosis, and radiation pneumonitis) or who are suspected to have these diseases by imaging at screening period

Has clinically significant corneal disease

Additional Exclusion Criteria for Dose Expansion Part:

Prior treatment with an govitecan derivative (eg, IMMU-132).

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

184

Study ID:

NCT02980341

Recruitment Status:

Active, not recruiting

Sponsor:

Daiichi Sankyo Co., Ltd.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 26 Locations for this study

See Locations Near You

Southeastern Regional Medical Center
Newnan Georgia, 30265, United States
Northwestern University
Chicago Illinois, 60611, United States
Massachusetts General Hospital
Boston Massachusetts, 02114, United States
Dana Farber Cancer Institute
Boston Massachusetts, 02215, United States
Albert Einstein College of Medicine
Bronx New York, 10467, United States
Memorial Sloan Kettering Cancer Center
New York New York, 10022, United States
Texas Oncology, P.A.
Dallas Texas, 75231, United States
UT Southwestern Medical Center
Dallas Texas, 75390, United States
University of Texas MD Anderson Cancer Center
Houston Texas, 77030, United States
Mays Cancer Center
San Antonio Texas, 78229, United States
National Hospital Organization Hokkaido Cancer Center
Sapporo-Shi Hokkaido, 003-0, Japan
National Cancer Center Hospital East
Chiba , 277-8, Japan
Fukushima Medical University Hospital
Fukushima , 960-1, Japan
Local Independent Administrative Corporation Hiroshima City Hospital Organization Hiroshima City Hiroshima Citizens Hospital
Hiroshima , 730-5, Japan
Hakuaikai Social Medical Corporation Sagara Hospital
Kagoshima , 892-0, Japan
Kanagawa Cancer Center
Kanagawa , 241-0, Japan
Kumamoto University Hospital
Kumamoto , 860-8, Japan
Aichi Cancer Center Hospital
Nagoya , 464-8, Japan
Nagoya City University Hospital
Nagoya , 467-8, Japan
National Hospital Organization Osaka National Hospital
Osaka , 540-0, Japan
Osaka International Cancer Institute
Osaka , 541-8, Japan
Kindai University Hospital
Osaka , 589-8, Japan
Saitama Medical University International Medical Center
Saitama , 350-1, Japan
Saitama Cancer Center
Saitama , 362 0, Japan
National Cancer Center Hospital
Tokyo , 104-0, Japan
The Cancer Institute Hospital of Japanese Foundation for Cancer Research
Tokyo , 135-8, Japan

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

184

Study ID:

NCT02980341

Recruitment Status:

Active, not recruiting

Sponsor:


Daiichi Sankyo Co., Ltd.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider